Trial Profile
A Double Blind, Single Dose Study To Explore The Safety, Pharmacokinetics And Pharmacodynamics Of PHA-794428 In Pediatric Patients With Growth Hormone Deficiency
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs PHA 794428 (Primary)
- Indications Dwarfism; Somatotropin deficiency
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Pfizer
- 16 May 2014 New trial record